An estimated 5.8 million Americans 65 and older are living with "alzheimers" (AD) disease (alzheimers is, unfortunately, a catch all term for any number of cognitive dysfunction pathologies). AD is the fifth leading cause of death in Americans over the age of 65 and an estimated cost for caring for folks with AD is $305 billion dollars. Presently, there is no cure within conventional/allopathic medicine. The drugs used only temporarily improve symptoms with numerous side effects. Historically, the primary cause of AD was thought to be the deposition of beta amyloid (amyloid plaques) with subsequent "tangles" and associated inflammation and, in fact, may certainly be a cause. However, we also know that the hippocampus, a part of the brain associated with memory and emotion, when chronically exposed to toxins/oxidative stress (in conjunction with inadequate nonrapid eye sleep during which the toxins are removed) can have a dramatic impact on cognitive function thu suggesting another, if not the primary, cause of AD. Along comes the endocannabinoid system (CBD and PEA (natural to the body) in this case. Several studies have demonstrated that CBD and PEA can reduce oxidative stress (ONEcbd has a combo CBD/astaxanthine specific for oxidative stress), inflammation and the formation of amyloid plaques. This results in a reduction of dementia related symptoms. A recent study in Neuroscisne (*/11/20) suggests that cannabidiol (CBD) improves blood flow to the hippocampus with the potential of addressing a range of conditions associated with altered memory, including AD, schizophrenia and PTSD.